Invasive pneumococcal disease surveillance Australia, 1 October to 31 December 2015

This quarterly report describes surveillance of invasive pneumococcal disease in Australia during the 4th quarter of 2015.

Page last updated: 11 April 2016

Rachel de Kluyver, Cindy Toms and the Enhanced Invasive Pneumococcal Disease Surveillance Working Group, for the Communicable Diseases Network Australia

Summary

The number of notified cases of invasive pneumococcal disease (IPD) in the 4th quarter of 2015 was fewer than the previous quarter and less than the number of notified cases in the 4th quarter of 2014. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups, since the 13vPCV replaced the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program from July 2011.

Key points

In the 4th quarter of 2015, there were 316 cases of IPD reported to the NNDSS. This was a 10% reduction on the number of cases reported for the same period in 2014 (n=352) (Table 1). For the calendar year, the total number of cases was similar to 2014 (n=1,543). For the reporting quarter and the 2015 calendar year, serotypes 3, 19A and 22F were the most common serotypes, which together accounted for 24% of annual cases (Table 2).

Table 1: Notified cases of invasive pneumococcal disease, Australia, 1 October to 31 December 2015, by Indigenous status, serotype completeness and state or territory
Indigenous status ACT NSW NT Qld SA Tas. Vic. WA Total qtr 4 2015 Total qtr 3 2015 Total qtr 4 2014 Year to date 2015

* Indigenous status completeness is defined as the reporting of a known Indigenous status, excluding the reporting of not stated or unknown Indigenous status.

† Serotype completeness is the proportion of all cases of invasive pneumococcal disease that were reported with a serotype or reported as non-typable. Serotype incompleteness may include when no isolate was available as diagnosis was by polymerase chain reaction and no molecular typing was attempted or was not possible due to insufficient genetic material; the isolate was not referred to the reference laboratory or was not viable; typing was pending at the time of reporting, or no serotype was reported by the notifying jurisdiction to the National Notifiable Diseases Surveillance System.

Indigenous 0 9 11 9 8 1 1 11 50 63 40 208
Non-Indigenous 2 78 1 39 23 12 55 22 232 453 271 1,120
Not stated/ unknown 0 10 0 0 0 0 24 0 34 73 41 171
Total 2 97 12 48 31 13 80 33 316 589 352 1,501
Indigenous status completeness* (%) 100 90 100 100 100 100 70 100 89
Serotype completeness (%) 100 89 100 98 81 100 93 91 91

Top of page

Table 2: Frequently notified serotypes of invasive pneumococcal disease, Australia, 1 October to 31 December 2015, by age group
Serotype Age group Serotype total*
Under 5 years 5 to 64 years Over 65 years

* Serotypes that only occur in less than 5 cases per quarter are grouped as Other and include non-typable samples this quarter.

† Serotype unknown includes those serotypes reported as no isolate, not referred, not viable, typing pending and untyped.

19A 4 13 13 30
22F 2 14 12 28
3 1 17 10 28
19F 3 8 9 20
23A 3 12 5 20
7F 0 12 4 16
23B 4 5 5 14
11A 0 4 8 12
8 1 7 4 12
9N 0 7 5 12
15A 1 5 5 11
16F 2 2 6 10
35B 0 3 6 9
6C 2 3 3 8
33F 2 2 2 6
12F 1 4 0 5
15C 2 1 2 5
Other 6 22 15 43
Serotype unknown 7 14 6 27
Total 41 155 120 316

Top of page

In non-Indigenous Australians, the number of notified cases was highest in the 60–64 years age group followed by the under 5 years age group. In Indigenous Australians, notified cases were highest in the under 5 years age group followed by the 50–54 years age group (Table 3). The proportion of cases reported as Indigenous increased to 16% compared with 11% in the 4th quarter of 2014 (http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3902p.htm).

Table 3: Notified cases of invasive pneumococcal disease, Australia, 1 October to 31 December 2015, by Indigenous status and age group
Age group Indigenous status* Total
Indigenous Non-Indigenous Not reported
* Indigenous status completeness is defined as the reporting of a known Indigenous status, excluding the reporting of not stated or unknown Indigenous status.
0–4 12 28 1 41
5–9 4 4 2 10
10–14 0 1 1 2
15–19 0 2 1 3
20–24 1 1 4 6
25–29 1 4 1 6
30–34 2 3 4 9
35–39 1 4 9 14
40–44 3 9 4 16
45–49 5 6 5 16
50–54 6 13 0 19
55–59 5 14 0 19
60–64 2 32 1 35
65–69 5 26 1 32
70–74 1 26 0 27
75–79 2 23 0 25
80–84 0 17 0 17
85+ 0 19 0 19
Total 50 (16%) 232 (73%) 34 (11%) 316

Top of page

There were 41 cases of IPD reported in children aged under 5 years. The number of cases in this age group for this reporting period was 28% less than the 4th quarter of 2014 (n=57). Of those cases with known serotype, 24% (n=8) were due to a serotype included in either the 7vPCV or the 13vPCV compared with 40% (n=21) of cases in the 4th quarter of 2014 (Figure 1). For the 2015 calendar year, there was a small reduction in the total number of cases aged less than 5 years (n=198) compared with 2014 (n=215) and a small decline in the annual rate from 14 per 100,000 in 2014 to 13 per 100,000 in 2015. Serotypes 23B and 19A continued to be the most common serotypes affecting this age group, noting that 19A is included in the 13vPCV (Table 2).

Figure 1: Notifications and annual rates* of invasive pneumococcal disease in children aged less than 5 years, Australia, 2004 to 2015, by vaccine serotype group

line and bar chart. Text description follows.

* Annual rates are shown on Q4.

Text version of Figure 1 (TXT 1 KB)

Top of page

In the 4th quarter of 2015, there were 7 cases reported in fully vaccinated children aged less than 5 years who were considered to be 13vPCV vaccine failures. For the 2015 calendar year, there were 44 13vPCV vaccine failures. Serotype 19A was reported as the cause of disease in 57% (n=4) of cases reported this period (Table 4) and 57% of vaccine failures in children aged less than 5 years this year.

Table 4: Characteristics of 13vPCV failures in children aged less than 5 years, Australia, 1 October to 31 December 2015
Age Indigenous status Serotype Clinical category Risk factor/s
1 year Non-Indigenous 19F Pneumonia No risk factor identified
1 year Non-Indigenous 3 Pneumonia No risk factor identified
2 years Non-Indigenous 19A Pneumonia No risk factor identified
2 years Non-Indigenous 19A Pneumonia Premature and other
3 years Non-Indigenous 19A Meningitis No risk factor identified
2 years Non-Indigenous 19A Pneumonia Childcare attendee and other
4 years Non-Indigenous 19F Meningitis Unknown

Top of page

There were 21 cases of IPD reported in Indigenous Australians aged 50 years or over. Of those cases with a reported serotype, 75% (n=15) were due to a serotype included in the 23-valent polysaccharide pneumococcal vaccine (23vPPV) (Figure 2). The number of notified cases of IPD in this age group was 10% higher than the previous quarter (n=19) and 43% more than the same quarter of 2014 (n=14). Compared with the previous quarter, the proportion of cases due to serotypes included in the 23vPPV increased markedly from 59% to 75% of cases with a reported serotype. During 2015, the annual rate increased to 77 per 100,000, a 22% increase from the 2014 rate of 63 per 100,000.

Figure 2: Notifications and annual rates* of all invasive pneumococcal disease in Indigenous Australians aged 50 years or over, Australia, 2004 to 2015, by vaccine serotype group

line and bar chart. Text description follows.

* Annual rates are shown on Q4.

Text version of Figure 2 (TXT 1 KB)

Top of page

There were 111 cases of IPD reported in non-Indigenous Australians aged 65 years or over. Of those cases with a reported serotype, 62% (n=66) were due to a serotype included in the 23vPPV (Figure 3). The number of notified cases of IPD in this age group was 16% less than in the 4th quarter of 2014 (n=132) and 48% lower than the previous quarter (n=213). Compared with the previous quarter, the proportion of IPD due to 23vPPV serotypes increased slightly from 61% to 62% of cases with a reported serotype. In the 2015 calendar year, the annual rate was 14 per 100,000, a 44% reduction from the peak rate of 2004 (25 per 100,000 population) and a small reduction on 2014 (16 per 100,000).

Figure 3: Notifications and annual rates* of all invasive pneumococcal disease in non-Indigenous Australians aged 65 years or over, Australia, 2004 to 2015, by vaccine serotype group

line and bar  chart. Text description follows.

* Annual rates are shown on Q4.

Text version of Figure 3 (TXT 1 KB)

Top of page

In this quarter there were 19 deaths attributed to 14 different IPD serotypes. There were 2 deaths reported in children aged under 5 years that were associated with serotype 19A and 6C respectively.

Notes

The data in this report are provisional and subject to change as laboratory results and additional case information become available. More detailed data analysis of IPD in Australia and surveillance methodology are described in the IPD annual report series published in Communicable Diseases Intelligence (CDI).

In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children, the medically at risk, and older Australians. More information on the scheduling of the pneumococcal vaccination can be found on the Immunise Australia Program web site (www.immunise.health.gov.au).

In this report, fully vaccinated describes cases that have completed the primary course of the relevant vaccine(s) required for their age according to the most recent edition of The Australian Immunisation Handbook, at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine. NB: A young child who has had all the required doses for their age but is not old enough to have completed the primary course would not be classified as fully vaccinated.

There are 4 pneumococcal vaccines available in Australia, each targeting multiple serotypes (Table 5). Note that in this report serotype analysis is generally grouped according to vaccine composition.

Table 5: Streptococcus pneumoniae serotypes targeted by pneumococcal vaccines
Vaccine type Serotypes targeted by the vaccine
7-valent pneumococcal conjugate vaccine (7vPCV) 4, 6B, 9V, 14, 18C, 19F and 23F
10-valent pneumococcal conjugate vaccine (10vPCV) 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
13-valent pneumococcal conjugate vaccine (13vPCV) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
23-valent pneumococcal polysaccharide vaccine (23vPPV) 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F

Top of page

Follow-up of all notified cases of IPD is undertaken in all states and territories except New South Wales and Victoria who conduct targeted follow-up of notified cases aged under 5 years, and 50 years or over for enhanced data.

Acknowledgements

This report was prepared with the assistance of Mr Mark Trungove and Ms Rachael Corvisy on behalf of the Enhanced Invasive Pneumococcal Disease Surveillance Working Group.

Enhanced Invasive Pneumococcal Disease Surveillance Working Group contributors to this report include (in alphabetical order): David Coleman (Tas.), Heather Cook (NT and secretariat), Rachel de Kluyver (Health), Carolien Giele (WA), Robin Gilmour (NSW), Vicki Krause (Chair), Rob Menzies (NCIRS), Shahin Oftadeh (Centre for Infectious Diseases and Microbiology– Public Health, Westmead Hospital), Sue Reid (ACT), Stacey Rowe (Vic.), Vitali Sintchenko (Centre for Infectious Diseases and Microbiology– Public Health, Westmead Hospital), Helen Smith (Queensland Health Forensic and Scientific Services), Janet Strachan (Microbiological Diagnostic Unit, University of Melbourne), Cindy Toms (Health), Hannah Vogt (SA), Angela Wakefield (Qld).

Author details

Corresponding author: Dr Rachel de Kluyver, Vaccine Preventable Diseases Surveillance Section, Office of Health Protection, Australian Government Department of Health, GPO Box 9484, MDP 14, Canberra, ACT 2601. Telephone: +61 2 6289 1463. Facsimile: +61 2 6289 1070. Email: Rachel.de.kluyver@health.gov.au

Top of page

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now